Outcome of Patients With Low-Risk and Intermediate-1-Risk Myelodysplastic Syndrome After Hypomethylating Agent Failure A Report on Behalf of the MDS Clinical Research Consortium

BACKGROUND: The hypomethylating agents (HMAs) azacitidine and decitabine are most commonly used to treat patients with higher-risk myelodysplastic syndromes (MDS). To the authors' knowledge, the prognosis of patients with low-risk and intermediate-1– risk MDS by the International Prognostic Sco...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer
Päätekijät: Jabbour, Elias J., Garcia-Manero, Guillermo, Strati, Paolo, Mishra, Asmita, Al Ali, Najla H., Padron, Eric, Lancet, Jeffrey, Kadia, Tapan, Daver, Naval, O'Brien, Susan, Steensma, David P., Sekeres, Mikkael A., Gore, Steven D., Dezern, Amy, Roboz, Gail J., List, Alan F., Kantarjian, Hagop M., Komrokji, Rami S.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2014
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4378905/
https://ncbi.nlm.nih.gov/pubmed/25410759
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.29145
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia